<DOC>
	<DOCNO>NCT02895191</DOCNO>
	<brief_summary>Compared placebo , evaluate effect safety Ulinastatin add conventional treatment ARDS ; Evaluate dose response relationship Ulinastatin ARDS .</brief_summary>
	<brief_title>The Safety Dose Response Relationship Ulinastatin Acute Respiratory Distress Syndrome ( ARDS )</brief_title>
	<detailed_description>After sign informed consent form patient surrogate , complete screen phase , patient fulfill inclusion exclusion criterion randomize 1:1:1:1 4 study arm . All Patients receive study treatment drug 7 14 day . Use Day 28 last patient cut-off day , Collect follow visit data Day 28 Day 90 patients．</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Urinastatin</mesh_term>
	<mesh_term>Trypsin Inhibitors</mesh_term>
	<criteria>1 . Have provide sign write informed consent form ( ICF ) patient patient 's legal representative ; 2 . Male Female patient ≥18 year age ; 3 . ARDS define use 2012 Berlin Criteria ; 4 . ARDS diagnose ≤72 hour , patient mechanically ventilate ( invasive noninvasive mechanical ventilation ) ; 5 ) 100mmhg &lt; PaO2/FiO2 &lt; 250mmhg CPAP/PEEP≥5 cmH2O . 1 . Patient known hypersensitivity Ulinastatin/adjuvant patient allergic constitution ; 2 . Presence 2 extrapulmonary fail organ failure accord SOFA； 3 . Cardiogenic pulmonary edema , cardiogenic pulmonary edema primary reason respiratory failure； 4 . Patients severe fungal infection septic shock ; 5 . ARDS cause burning , drown , poison ; 6 . Presence severe chronic liver disease ( ChildPugh score 1215 ) ，or severe chronic respiratory disease PaCO2 &gt; 50 mmHg use home oxygen ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>